95 related articles for article (PubMed ID: 21852128)
1. RGD mimetics containing phthalimidine fragment as novel ligands of fibrinogen receptor.
Krysko AA; Samoylenko GV; Polishchuk PG; Andronati SA; Kabanova TA; Khristova TM; Kuz'min VE; Kabanov VM; Krysko OL; Varnek AA; Grygorash RY
Bioorg Med Chem Lett; 2011 Oct; 21(19):5971-4. PubMed ID: 21852128
[TBL] [Abstract][Full Text] [Related]
2. Derivatives of tetrahydroisoquinoline: synthesis and initial evaluation of novel non-peptide antagonists of the alpha(IIb)beta(3)-integrin.
Krysko AA; Krysko OL; Kabanova TA; Andronati SA; Kabanov VM
Bioorg Med Chem Lett; 2010 Aug; 20(15):4444-6. PubMed ID: 20598885
[TBL] [Abstract][Full Text] [Related]
3. Peptidomimetics - antagonists of the fibrinogen receptors: molecular design, structures, properties and therapeutic applications.
Andronati SA; Karaseva TL; Krysko AA
Curr Med Chem; 2004 May; 11(9):1183-211. PubMed ID: 15134514
[TBL] [Abstract][Full Text] [Related]
4. Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists.
Malovichko OL; Petrus AS; Krysko AA; Kabanova TA; Andronati SA; Karaseva TL; Kiriyak AV
Bioorg Med Chem Lett; 2006 Oct; 16(20):5294-7. PubMed ID: 16919941
[TBL] [Abstract][Full Text] [Related]
5. Novel fibrinogen receptor antagonists. RGDF mimetics, derivatives of 4-(isoindoline-5-yl)amino-4-oxobutyric acid.
Krysko AA; Chugunov BM; Malovichko OL; Andronati SA; Kabanova TA; Karaseva TL; Kiriyak AV
Bioorg Med Chem Lett; 2004 Nov; 14(22):5533-5. PubMed ID: 15482918
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, biological evaluation and molecular docking studies of 2-piperazin-1-yl-quinazolines as platelet aggregation inhibitors and ligands of integrin αIIbβ3.
Krysko AA; Kornylov AY; Polishchuk PG; Samoylenko GV; Krysko OL; Kabanova TA; Kravtsov VCh; Kabanov VM; Wicher B; Andronati SA
Bioorg Med Chem Lett; 2016 Apr; 26(7):1839-43. PubMed ID: 26912112
[TBL] [Abstract][Full Text] [Related]
7. Derivatives of 1,2,3,4-tetrahydroisoquinoline-7-carboxylic acid as novel fibrinogen receptor antagonists.
Malovichko OL; Krysko AA; Kabanova TA; Andronati SA; Grishkovets VI; Kachala VV; Panov DA
Med Chem; 2009 Mar; 5(2):158-64. PubMed ID: 19275714
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, biological evaluation, X-ray molecular structure and molecular docking studies of RGD mimetics containing 6-amino-2,3-dihydroisoindolin-1-one fragment as ligands of integrin αIIbβ₃.
Krysko AA; Samoylenko GV; Polishchuk PG; Fonari MS; Kravtsov VCh; Andronati SA; Kabanova TA; Lipkowski J; Khristova TM; Kuz'min VE; Kabanov VM; Krysko OL; Varnek AA
Bioorg Med Chem; 2013 Aug; 21(15):4646-61. PubMed ID: 23757209
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel platelet fibrinogen receptor antagonists with 2H-1,4-benzoxazine-3(4H)-one scaffold. A systematic study.
Anderluh M; Cesar J; Stefanic P; Kikelj D; Janes D; Murn J; Nadrah K; Tominc M; Addicks E; Giannis A; Stegnar M; Dolenc MS
Eur J Med Chem; 2005 Jan; 40(1):25-49. PubMed ID: 15642407
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
Varon D; Lider O; Dardik R; Shenkman B; Alon R; Hershkoviz R; Kapustina G; Savion N; Martinowitz U; Greenspoon N
Thromb Haemost; 1993 Dec; 70(6):1030-6. PubMed ID: 8165596
[TBL] [Abstract][Full Text] [Related]
11. Construction of drug screening cell model and application to new compounds inhibiting FITC-fibrinogen binding to CHO cells expressing human alphaIIbbeta3.
Yang J; Yao J; Chen J; Wang XN; Zhu TY; Chen LL; Chu P
Eur J Pharmacol; 2009 Sep; 618(1-3):1-8. PubMed ID: 19619528
[TBL] [Abstract][Full Text] [Related]
12. New platelet fibrinogen receptor glycoprotein IIb-IIIa antagonists: orally active series of N-alkylated amidines with a 6,6-bicyclic template.
Okumura K; Shimazaki T; Aoki Y; Yamashita H; Tanaka E; Banba S; Yazawa K; Kibayashi K; Banno H
J Med Chem; 1998 Oct; 41(21):4036-52. PubMed ID: 9767641
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and antiaggregatory activity of RGD-peptidomimetics based on 4-oxo-4-(piperazine-1-yl)butyric acid as Arg-mimetic.
Andronati SA; Krysko AA; Kabanov VM; Kabanova TA; Karaseva TL; Chugunov BM; Meshkova SB; Topilova ZM
Acta Pol Pharm; 2003; 60(5):375-81. PubMed ID: 15005421
[TBL] [Abstract][Full Text] [Related]
14. Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities.
Stefanic Anderluh P; Anderluh M; Ilas J; Mravljak J; Sollner Dolenc M; Stegnar M; Kikelj D
J Med Chem; 2005 May; 48(9):3110-3. PubMed ID: 15857114
[TBL] [Abstract][Full Text] [Related]
15. Platelet glycoprotein IIb/IIIa receptor antagonists derived from isoxazolidines.
Confalone PN; Jin F; Mousa SA
Bioorg Med Chem Lett; 1999 Jan; 9(1):55-8. PubMed ID: 9990456
[TBL] [Abstract][Full Text] [Related]
16. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.
Mousa SA; Bozarth JM; Naik UP; Slee A
Br J Pharmacol; 2001 Jun; 133(3):331-6. PubMed ID: 11375248
[TBL] [Abstract][Full Text] [Related]
17. Novel non-peptide fibrinogen receptor antagonists. 1. Synthesis and glycoprotein IIb-IIIa antagonistic activities of 1,3,4-trisubstituted 2-oxopiperazine derivatives incorporating side-chain functions of the RGDF peptide.
Sugihara H; Fukushi H; Miyawaki T; Imai Y; Terashita Z; Kawamura M; Fujisawa Y; Kita S
J Med Chem; 1998 Feb; 41(4):489-502. PubMed ID: 9484499
[TBL] [Abstract][Full Text] [Related]
18. Use of conformationally restricted benzamidines as arginine surrogates in the design of platelet GPIIb-IIIa receptor antagonists.
Sall DJ; Arfsten AE; Bastian JA; Denney ML; Harms CS; McCowan JR; Morin JM; Rose JW; Scarborough RM; Smyth MS; Um SL; Utterback BG; Vasileff RT; Wikel JH; Wyss VL; Jakubowski JA
J Med Chem; 1997 Aug; 40(18):2843-57. PubMed ID: 9288166
[TBL] [Abstract][Full Text] [Related]
19. Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor.
Barre DE
Thromb Res; 2007; 119(5):601-7. PubMed ID: 16860375
[TBL] [Abstract][Full Text] [Related]
20. FcgammaRII mediates platelet aggregation caused by disintegrins and GPIIb/IIIa monoclonal antibody, AP2.
Huang TF; Chang CH; Ho PL; Chung CH
Exp Hematol; 2008 Dec; 36(12):1704-13. PubMed ID: 18809237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
